NCT04203680

Brief Summary

Background: In cardiac surgery, myocardial protection is mandatory during cross clamp time followed by reperfusion. Use of cardioplegic solutions preserves myocardial energy stores, hindering electrolyte disturbances and acidosis during periods of myocardial ischemia. This study was designed to compare the efficacy and safety of Histidine-tryptophan-ketoglutarate (HTK) solution versus blood cardioplegia in coronary artery bypass graft surgery. Methods: Three hundred and twenty patients were randomized into Histidine-tryptophan-ketoglutarate (HTK) group and blood cardioplegia group. Ventilation time, total bypass time, cross clamp time, length of ICU or hospital stay and the early postoperative outcomes were analysed.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
320

participants targeted

Target at P75+ for early_phase_1

Timeline
Completed

Started Dec 2019

Shorter than P25 for early_phase_1

Geographic Reach
1 country

2 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

December 16, 2019

Completed
2 days until next milestone

First Posted

Study publicly available on registry

December 18, 2019

Completed
7 days until next milestone

Study Start

First participant enrolled

December 25, 2019

Completed
3 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 31, 2020

Completed
25 days until next milestone

Study Completion

Last participant's last visit for all outcomes

April 25, 2020

Completed
Last Updated

May 7, 2020

Status Verified

May 1, 2020

Enrollment Period

3 months

First QC Date

December 16, 2019

Last Update Submit

May 5, 2020

Conditions

Outcome Measures

Primary Outcomes (1)

  • mortality rate

    mortality rate

    up to 30 days postoperative

Secondary Outcomes (3)

  • Troponin I level

    Up to 24 hours postoperative

  • length of ICU stay

    up to 3 days postoperative

  • length of hospital stay

    up to 7 days postoperative

Study Arms (2)

HTK group

SHAM COMPARATOR

Patients received 30 ml/kg of HTK cardioplegic solution at 4°C through an antegrade fashion at an initial perfusion pressure of 80-100 mmHg

Drug: HTK cardioplegic solution

blood cardioplegia group

ACTIVE COMPARATOR

patients received one liter of blood cardioplegia was given with the antegrade route at 30°C, or lower. Blood maintenance cardioplegia was repeated every 30-45mins

Drug: blood cardioplegia

Interventions

30 ml/kg of HTK cardioplegic solution at 4°C through an antegrade fashion at an initial perfusion pressure of 80-100 mmHg

Also known as: Histidine-tryptophan-ketoglutarate solution
HTK group

one liter of blood cardioplegia was given with the antegrade route at 30°C, or lower. Blood maintenance cardioplegia was repeated every 30-45mins

blood cardioplegia group

Eligibility Criteria

Age60 Years - 80 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • age from 60-80 years old
  • elective CABG
  • no comorbidities

You may not qualify if:

  • patients with Unstable angina
  • Poor left ventricular function
  • Patient with acute myocardial infarction
  • previous renal failure
  • Preoperative Aortic valve or Mitral valve disease requiring replacement

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

Ain Shams university

Cairo, 11566, Egypt

Location

Ain Shams university

Cairo, Egypt

Location

MeSH Terms

Interventions

Bretschneider cardioplegic solution

Study Officials

  • Ayman shoeb

    Ain Shams University

    STUDY CHAIR

Study Design

Study Type
interventional
Phase
early phase 1
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assistant professor of Anaesthesiology

Study Record Dates

First Submitted

December 16, 2019

First Posted

December 18, 2019

Study Start

December 25, 2019

Primary Completion

March 31, 2020

Study Completion

April 25, 2020

Last Updated

May 7, 2020

Record last verified: 2020-05

Data Sharing

IPD Sharing
Will share

study protocol

Shared Documents
STUDY PROTOCOL, SAP, ICF
Time Frame
4 months
Access Criteria
Data were analyzed using SPSS Statistics version 23 (IBM© Corp., Armonk, NY, USA). Normally distributed numerical data were presented as mean and SD, and skewed data were presented as median and interquartile range. Qualitative data were presented as number and percentage or ratio. Normally distributed numerical data were compared using the unpaired t-test. Skewed numerical data were compared using the Mann-Whitney test and categorical data were compared using Fisher's exact test. P-value \< 0.05 were considered statistically significant.

Locations